A growing body of evidence points to a specific early failure as a key trigger of SLE: the body's normal process for clearing apoptotic (naturally dying) cell debris is impaired. Ordinarily, this debris — including nuclear material not normally visible to the immune system — is cleared quickly and quietly. In SLE, defects in complement proteins, in enzymes that break down nucleic acids (like DNase and RNase), and in Fc receptors allow this debris to persist and accumulate. Antigen-presenting cells then take up this lingering nuclear material and present it to B and T lymphocytes, setting off the production of antinuclear antibodies that define the disease. This reframes SLE partly as a disease of failed cellular "clean-up," with the autoimmune cascade that follows being a consequence of that initial clearance failure rather than the primary problem — opening a possible future therapeutic angle focused on restoring or substituting for defective clearance mechanisms rather than only suppressing the downstream immune response.